HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.

Related Articles

HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.

Curr Cancer Drug Targets. 2017 Mar 30;:

Authors: Sammons SL, Topping DL, Blackwell KL

Abstract
Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Addition of a CDK4/6 inhibitor to endocrine therapy increases efficacy and delays disease progression. Successful use of CDK4/6 inhibitor-based therapies in the clinic requires insight into the unique side-effect profiles of this class of agents and effective patient monitoring. In this review, we discuss the mode of action of the three CDK4/6 inhibitors in late clinical development - palbociclib (PD-0332991; Pfizer), ribociclib (LEE011; Novartis), and abemaciclib (LY2835219; Lilly) - and we describe the efficacy and safety data relating to their use in HR+, HER2- advanced breast cancer. In addition, we define the side-effect profile of each agent, implications for patient monitoring, and considerations for patient care providers and pharmacists.

PMID: 28359238 [PubMed - as supplied by publisher]

http://ift.tt/2nW1QFR